The Parkinson's Progression Markers Initiative (PPMI) is a landmark five-year clinical study aiming to identify biomarkers of Parkinson's disease progression, supported by The Michael J. Fox Foundation. People recently diagnosed with PD who are not currently taking medications are needed — and so are individuals who don't have PD (or even a close relative with PD) to serve as controls.
|
 |
Hear from Michael about getting involved  |
 |
Read more from Michael about PPMI |
|
 |
||||
 |
PPMI Overview and FAQs Learn more about the study's goals, timeframe and enrollment eligibility |
 |
PPMI in the News Find the latest news and announcements about the study  |
|
|
||||
 |
||||
 |
Find a Site Near You PPMI is coming to 18 cities and towns in the United States and Europe – find the site nearest you |
 |
Sign Up for Updates Want to participate in clinical research? Sign up for TrialsFlash, MJFF's email updates on clinical trials, including PPMI |
|
 |
||||
 |
Biomarkers and PD Ken Marek, MD, principal investigator of PPMI, talks biomarkers with KQED’s Dave Iverson Click here to read the transcript |
 |
Q&A: Biomarkers Learn how biomarkers impact patients' lives from diagnosis to drug development |
|
